Nexien BioPharma to File Pre-IND Meeting Request with the FDA February 27, 2019 Rob Meagher Medical Marijuana 0 Comments PRESS RELEASE Encouraging clinical observations and patient questionnaire results indicate that specific cannabinoid formulations are supportive in the treatment of patients suffering from myotonic dystrophy DENVER--(BUSINESS WIRE)--Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company… Read More→